Defenders say that the partnership will likely bring a lifesaving treatment to patients , something the government the government really do by itself , and the government that is what matters most .Critics say that taxpayers will end up paying twice for the same drug   —    once to support its development and the same drug   second time to buy it   — the same drug   while the company reaps the financial benefit ."If this was not a    cancer treatment   —    if it was for a new solar technology , for example   —    